後天性希少血液疾患の世界市場研究

• 英文タイトル:Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share

Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share「後天性希少血液疾患の世界市場研究」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301E023
• 出版社/出版日:Persistence Market Research / 2022年10月4日
• レポート形態:英文、PDF、250ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥735,000 (USD4,900)▷ お問い合わせ
  Site Licence¥1,140,000 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,590,000 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の後天性希少血液疾患市場の現状について調査しています。本レポートでは、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、需要分析・予測、価格分析、市場背景、治療別(血液凝固因子製剤、免疫グロブリン製剤治療、活性化プロトロンビン複合体製剤、トロンボポエチン受容体作動薬)、適応疾患別(後天性無顆粒球症、後天性血友病、後天性フォンウィルブランド症候群、発作性夜間血色素尿症(PNH)、その他)、流通チャネル別(病院薬局、小売薬局、その他)、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア太平洋、中東・アフリカ)分析、構造分析、競争分析、仮定、調査方法などをまとめております。本レポートには、Alexion Pharmaceuticals, Inc.、Amgen, Inc.、Celgene Corporation、Eli Lilly and Company、Sanofi S.A.、GlaxoSmithKline plc.、Cyclacel Pharmaceuticals, Inc.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・主要成功要因
・需要分析・予測
・価格分析
・市場背景
・世界の後天性希少血液疾患市場規模:治療別
- 血液凝固因子製剤における市場規模
- 免疫グロブリン製剤治療における市場規模
- 活性化プロトロンビン複合体製剤における市場規模
- トロンボポエチン受容体作動薬における市場規模
・世界の後天性希少血液疾患市場規模:適応疾患別
- 後天性無顆粒球症における市場規模
- 後天性血友病における市場規模
- 後天性フォンウィルブランド症候群における市場規模
- 発作性夜間血色素尿症(PNH)における市場規模
- その他における市場規模
・世界の後天性希少血液疾患市場規模:地域別
- 北米の後天性希少血液疾患市場規模
- 中南米の後天性希少血液疾患市場規模
- ヨーロッパの後天性希少血液疾患市場規模
- 東アジアの後天性希少血液疾患市場規模
- 南アジア太平洋の後天性希少血液疾患市場規模
- 中東・アフリカの後天性希少血液疾患市場規模
・構造分析
・競争分析
・仮定
・調査方法

Acquired Orphan Blood Disease Market: Report Scope

The latest market report by Persistence Market Research on the global acquired orphan blood disease market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides a detailed assessment of key market dynamics and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with an acquired orphan blood disease. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to the compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on future trends in the market. Furthermore, new and emerging players in the global acquired orphan blood disease market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the acquired orphan blood disease market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research’s report on the global acquired orphan blood disease market offers information divided into four segments – therapy, disease indication, distribution channel, and region.

Therapy

Recombinant Factor
Immunoglobulin Infusion Therapy
Activated Prothrombin Complex Concentrate
Thrombopoietin Receptor Agonists
Others
Disease Indication

Acquired Agranulocytosis
Acquired Hemophilia
Acquired Von Willebrand Syndrome
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic Syndrome
Other
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others
Region

North America
Europe
Latin America
East Asia
The Middle East & Africa
South Asia & Pacific
Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global acquired orphan blood disease industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global acquired orphan blood disease market?
Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global acquired orphan blood disease market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions – North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research
Secondary Research
Trade Research
Social Media Research

レポート目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Strategic Promotional Strategies

5. Global Acquired Orphan Blood Disease Market Demand Analysis 2017–2021 and Forecast, 2022–2032

    5.1. Historical Market Volume (Tons) Analysis, 2017–2021

    5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

    5.3. Y-o-Y Growth Trend Analysis

6. Global Acquired Orphan Blood Disease Market – Pricing Analysis

    6.1. Regional Pricing Analysis By Therapy

    6.2. Global Average Pricing Analysis Benchmark

7. Global Acquired Orphan Blood Disease Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Industry Value Added Overview

        8.1.3. Global Infrastructure Investment Overview

        8.1.4. Global Construction Spending Analysis

        8.1.5. Other Macro Economic Factors

    8.2. Forecast Factors – Relevance & Impact

        8.2.1. Top Companies Historical Growth

        8.2.2. GDP Growth forecast

        8.2.3. Construction Industry forecast

        8.2.4. Distribution Channel Growth Outlook

        8.2.5. Collaboration Activities

    8.3. Value Chain

        8.3.1. Raw Material Suppliers

        8.3.2. List of Manufacturers

        8.3.3. List of Distributors

    8.4. COVID-19 Crisis – Impact Assessment

        8.4.1. Current Statistics

        8.4.2. Short-Mid-Long Term Outlook

        8.4.3. Likely Rebound

    8.5. Market Dynamics

        8.5.1. Drivers

        8.5.2. Restraints

        8.5.3. Opportunity Analysis

        8.5.4. Trends

9. Global Acquired Orphan Blood Disease Market Analysis 2017–2021 and Forecast 2022–2032, by Therapy

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

    9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Therapy 2022–2032

        9.3.1. Recombinant Factor

        9.3.2. Immunoglobulin Infusion Therapy

        9.3.3. Activated Prothrombin Complex Concentrate

        9.3.4. Thrombopoietin Receptor Agonists

        9.3.5. Others

    9.4. Market Attractiveness Analysis by Therapy

10. Global Acquired Orphan Blood Disease Market Analysis 2017–2021 and Forecast 2022–2032, By Disease Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Disease Indication, 2017–2021

    10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Disease Indication, 2022–2032

        10.3.1. Acquired Agranulocytosis

        10.3.2. Acquired Hemophilia

        10.3.3. Acquired Von Willebrand Syndrome

        10.3.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)

        10.3.5. Myelodysplastic Syndrome

        10.3.6. Others

    10.4. Market Attractiveness Analysis By Disease Indication

11. Global Acquired Orphan Blood Disease Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

    11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Acquired Orphan Blood Disease Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

    12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia and Pacific

        12.3.6. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Acquired Orphan Blood Disease Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

        13.4.1. By Country

            13.4.1.1. U.S.

            13.4.1.2. Canada

        13.4.2. By Type

        13.4.3. By Disease Indication

        13.4.4. By Distribution Channel

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By Disease Indication

        13.5.4. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants – Intensity Mapping

    13.8. Drivers and Restraints – Impact Analysis

14. Latin America Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Rest of Latin America

        14.4.2. By Type

        14.4.3. By Disease Indication

        14.4.4. By Distribution Channel

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By Disease Indication

        14.5.4. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants – Intensity Mapping

    14.8. Drivers and Restraints – Impact Analysis

15. Europe Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

    15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. U.K.

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Rest of Europe

        15.4.2. By Type

        15.4.3. By Disease Indication

        15.4.4. By Distribution Channel

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By Disease Indication

        15.5.4. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants – Intensity Mapping

    15.8. Drivers and Restraints – Impact Analysis

16. South Asia and Pacific Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. India

            16.4.1.2. ASEAN

            16.4.1.3. Oceania

            16.4.1.4. Rest of South Asia & Pacific

        16.4.2. By Type

        16.4.3. By Disease Indication

        16.4.4. By Distribution Channel

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Type

        16.5.3. By Disease Indication

        16.5.4. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants – Intensity Mapping

    16.8. Drivers and Restraints – Impact Analysis

17. East Asia Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        17.4.1. By Country

            17.4.1.1. China

            17.4.1.2. Japan

            17.4.1.3. South Korea

        17.4.2. By Type

        17.4.3. By Disease Indication

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Type

        17.5.3. By Disease Indication

        17.5.4. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants – Intensity Mapping

    17.8. Drivers and Restraints – Impact Analysis

18. Middle East and Africa Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        18.4.1. By Country

            18.4.1.1. GCC Countries

            18.4.1.2. Turkey

            18.4.1.3. Northern Africa

            18.4.1.4. South Africa

            18.4.1.5. Rest of Middle East and Africa

        18.4.2. By Type

        18.4.3. By Disease Indication

        18.4.4. By Distribution Channel

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Type

        18.5.3. By Disease Indication

        18.5.4. By Distribution Channel

    18.6. Market Trends

    18.7. Key Market Participants – Intensity Mapping

    18.8. Drivers and Restraints – Impact Analysis

19. Emerging Countries Acquired Orphan Blood Disease Market Analysis

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Acquired Orphan Blood Disease Market Analysis

        19.2.1. By Type

        19.2.2. By Disease Indication

        19.2.3. By Distribution Channel

    19.3. Canada Acquired Orphan Blood Disease Market Analysis

        19.3.1. By Type

        19.3.2. By Disease Indication

        19.3.3. By Distribution Channel

    19.4. Mexico Acquired Orphan Blood Disease Market Analysis

        19.4.1. By Type

        19.4.2. By Disease Indication

        19.4.3. By Distribution Channel

    19.5. Brazil Acquired Orphan Blood Disease Market Analysis

        19.5.1. By Type

        19.5.2. By Disease Indication

        19.5.3. By Distribution Channel

    19.6. Germany Acquired Orphan Blood Disease Market Analysis

        19.6.1. By Type

        19.6.2. By Disease Indication

        19.6.3. By Distribution Channel

    19.7. Italy Acquired Orphan Blood Disease Market Analysis

        19.7.1. By Type

        19.7.2. By Disease Indication

        19.7.3. By Distribution Channel

    19.8. France Acquired Orphan Blood Disease Market Analysis

        19.8.1. By Type

        19.8.2. By Disease Indication

        19.8.3. By Distribution Channel

    19.9. U.K. Acquired Orphan Blood Disease Market Analysis

        19.9.1. By Type

        19.9.2. By Disease Indication

        19.9.3. By Distribution Channel

    19.10. Spain Acquired Orphan Blood Disease Market Analysis

        19.10.1. By Type

        19.10.2. By Disease Indication

        19.10.3. By Distribution Channel

    19.11.  BENELUX Acquired Orphan Blood Disease Market Analysis

        19.11.1. By Type

        19.11.2. By Disease Indication

        19.11.3. By Distribution Channel

    19.12. Russia Acquired Orphan Blood Disease Market Analysis

        19.12.1. By Type

        19.12.2. By Disease Indication

        19.12.3. By Distribution Channel

    19.13. China Acquired Orphan Blood Disease Market Analysis

        19.13.1. By Type

        19.13.2. By Disease Indication

        19.13.3. By Distribution Channel

    19.14. Japan Acquired Orphan Blood Disease Market Analysis

        19.14.1. By Type

        19.14.2. By Disease Indication

        19.14.3. By Distribution Channel

    19.15. S. Korea Acquired Orphan Blood Disease Market Analysis

        19.15.1. By Type

        19.15.2. By Disease Indication

        19.15.3. By Distribution Channel

    19.16. India Acquired Orphan Blood Disease Market Analysis

        19.16.1. By Type

        19.16.2. By Disease Indication

        19.16.3. By Distribution Channel

    19.17. ASEAN Acquired Orphan Blood Disease Market Analysis

        19.17.1. By Type

        19.17.2. By Disease Indication

        19.17.3. By Distribution Channel

    19.18. Australia and New Zealand Acquired Orphan Blood Disease Market Analysis

        19.18.1. By Type

        19.18.2. By Disease Indication

        19.18.3. By Distribution Channel

    19.19.  GCC Countries Acquired Orphan Blood Disease Market Analysis

        19.19.1. By Type

        19.19.2. By Disease Indication

        19.19.3. By Distribution Channel

    19.20. Turkey Acquired Orphan Blood Disease Market Analysis

        19.20.1. By Type

        19.20.2. By Disease Indication

        19.20.3. By Distribution Channel

    19.21. Northern Africa Acquired Orphan Blood Disease Market Analysis

        19.21.1. By Type

        19.21.2. By Disease Indication

        19.21.3. By Distribution Channel

    19.22. South Africa Acquired Orphan Blood Disease Market Analysis

        19.22.1. By Type

        19.22.2. By Disease Indication

        19.22.3. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. Alexion Pharmaceuticals, Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

        21.3.2. Amgen, Inc.

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

        21.3.3. Celgene Corporation

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

        21.3.4. Eli Lilly and Company

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

        21.3.5. Sanofi S.A.

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

        21.3.6. GlaxoSmithKline plc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

        21.3.7. Cyclacel Pharmaceuticals, Inc.

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

        21.3.8. Onconova Therapeutics, Inc.

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

        21.3.9. Incyte Corporation

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

        21.3.10. CTI BioPharma Corp.

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.10.4. Sales Footprint

            21.3.10.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology




• 英文レポート名:Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share
• 日本語訳:後天性希少血液疾患の世界市場研究
• レポートコード:MRC2301E023お問い合わせ(見積依頼・ご注文・質問)